U.S. Patent No. 10,300,494 was issued on May 28, 2019, to Tetragrow, Inc. of Calistoga, California. The claims of the '494 patent recite a method for trichome separation from cannabis by agitation and then floatation of the removed trichomes in water. Claim 1 of the '494 patent reads as follows (emphasis added):
U.S. Patent No. 10,239,808 was issued on March 26, 2019, to Canopy Holdings, LLC of Littleton, Colorado. The claims of the '808 patent recite a two-solvent silica gel chromatography method for cannabinoid purification. Claim 1 of the ’808 patent reads as follows (emphasis added):
evaporating ethanol from the treated crude oil and ethanol mixture to leave oil; washing the oil with brine;
Alcohol Extraction, Distillation and Crystallization
Freeze Dry and Extract
wherein the extracting of the Δ9-THC carboxylic acid from the heptane results in the formation of three layers consisting of a first organic layer, a second oily layer, and third aqueous layer.
U.S. Patent Nos. 10,059,684 and 10,246,431 were issued on August 8, 2018, and April 2, 2019, respectively, to AXIM Biotechnologies, Inc. of New York, New York. The claims of the '684 and '431 patents recite a method for separating THC-A from cannabis by heptane extraction followed by separation using basic sodium chloride solution. The sole claim of the '684 patent reads as follows (emphasis added):
It has been found that from the extracts of hemp (Cannabis sativa or Cannabis indicia) a red viscous oil can be obtained, commonly known as red oil, from which a pure crystalline compound, cannabidiol, can be isolated (Adams, Hunt and Clark, J. A. C. S. 62, 196 (1940). Through a chemical study (J. A. C. S. 62, 196, 732, 735, 1770 (1940); see also J. A. C. S. August and September numbers, 1940), it has been shown to have the structural formula: CH3 OH C OH CH3 CH2 (Formula I) With the exception of the position of the double 20 bond in the left hand cycle in the above formula the structure of cannabidiol is well established.
Investigations show this left hand cycle to be a tetrahydro benzene ring.
It has an [a]27D-125°, and is physiologically inactive so far as marihuana activity is concerned.
The benzene solution was washed with dilute hydrochloric acid, then with aqueous sodium bicarbonate and finally with water. The benzene was evaporated and the residue was dissolved in 500 cc. of dry ether. This solution was treated with norit (20 grams), filtered, and then concentrated to 300 cc. On cooling in an ice-salt mixture with constant stirring, crystallization set Sin. After one hour, the product was filtered and washed with cold dry ether. Upon purification of the desired product by recrystallization from 800 cc. of a mixture of methanol and methyl acetate (2:1), it was obtained as white rods M. P. 106-107′ C. (corr.).
The process as set forth in the J. A. C. S. 62, 55 196, 198, 199 (1940) serves to illustrate the present invention.
The invention claimed is:
Cannabinol (CBN) is a mildly psychotropic cannabinoid naturally found in the Cannabis sativa plant. It is a relatively weak CB1 and CB2 receptor agonist, with an order of magnitude less affinity than (-)-trans-.DELTA..sup.9-Tetrahydrocannabinol (.DELTA..sup.9-THC) (Pertwee 2008). It has been suggested anecdotally, and in at least one clinical study (Karniol et al. 1975), that CBN causes increased drowsiness in comparison to (-)-trans-.DELTA..sup.9-Tetrahydrocannabinol (.DELTA.9-TI-IC). According to CDC, “4% of US adults aged 20 and over used prescription sleep aids in the past month” (Chong et al. 2013). Many prescription sleep aids carry inherent risk, including dependence in many cases. Thus, a market exists for naturally-derived sleep aids.
16. The method of claim 15, wherein the cannabis extract enriched in cannabinol also comprises cannabidiol.
One embodiment of the present disclosure is directed to a method for preparing a whole-plant hemp extract based product, the method comprising: extracting cannabinoids from plant materials (such as one or more hemp varieties of Cannabis sativa), separating and purifying CBD from the extracted cannabinoids; converting purified CBD to .DELTA.9-THC and .DELTA.8-THC and concurrently converting .DELTA.9-THC to CBN; purifying and separating the CBN; and combining the purified CBN with a whole-plant hemp extract. The method can include combining a carrier, such as a carrier oil and/or at least one further cannabinoid with the purified CBN and the whole-plant hemp extract, such as CBD, CBC, CBG, and/or CBDV.
7. The method of claim 3, wherein the cannabis extract enriched in cannabinol has a cannabinol:cannabidiol w:w ratio between 20:1 to 1:20.